SISRAM MED (01696) has issued an announcement regarding the proposed restructuring at the controlling shareholder level. According to the restructuring announcement, an indirect wholly-owned subsidiary of Fosun Pharma, Neng Yue, entered into agreements with Chindex International, respectively, agreeing to transfer all of their equity interests in the company (collectively representing approximately 71.42% of the company's total issued shares as of the date of this announcement) to another indirect wholly-owned subsidiary of Fosun Pharma, FPI. On April 22, 2026, the company's board of directors received a notification from Fosun Pharma stating that, pursuant to the terms of their agreements, this restructuring has been completed. Consequently, as of the date of this announcement, FPI, an indirect wholly-owned subsidiary of Fosun Pharma, holds 334.5 million shares of the company, and the proportion of the company's equity indirectly held by Fosun Pharma remains unchanged.